NASDAQ:ARIA Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ARIA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ariad Pharmaceuticals alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Ariad Pharmaceuticals Stock (NASDAQ:ARIA)ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. ARIA Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 12, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 8, 2024 | msn.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 4, 2024 | bizjournals.comTakeda extends lease in Kendall Square through 2040February 13, 2024 | finance.yahoo.comIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesJanuary 3, 2024 | msn.comVeteran biotech entrepreneur Harvey Berger to lead startup Kojin TherapeuticsJanuary 3, 2024 | bizjournals.comHarvey Berger leaves biotech 'sidelines' for new CEO gigApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 26, 2023 | msn.comBiogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentOctober 12, 2023 | benzinga.comLeukemia Therapeutics Treatment Market Set to Achieve US$ 30,318.5 Million by 2033 at 7.1% CAGR | Future Market Insights Inc.September 6, 2023 | fortune.comKickstarter’s new finance chief is ultra-extroverted—and she credits that trait to her success as a ‘people-centric CFO’August 24, 2023 | finance.yahoo.comChronic Lymphocytic Leukemia Treatment Global Market Report 2023August 20, 2023 | thestreet.comAriad Stock Falls On Unusually High Volume (ARIA)July 19, 2023 | msn.comSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearJuly 17, 2023 | cbsnews.comSecond Alzheimer's drug to slow disease's progression may be approved in the US this yearJune 28, 2023 | finance.yahoo.comSarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard GaynorJune 26, 2023 | washingtonpost.comActivist Pro Tip: Don’t Put Your Girlfriend on the BoardMay 17, 2023 | marketwatch.comPonatinib Market Research | 2023-2030May 16, 2023 | marketwatch.comComprehensive Analysis of Cancer Treatment Drugs Market Trends and Growth 2023-2030May 14, 2023 | marketwatch.comIclusig Market Research | 2023-2030May 10, 2023 | marketwatch.comUterine Cancer Therapies and Diagnostic Market Forecast 2023-2030May 5, 2023 | marketwatch.comThe Global Targeted Drugs for NSCLC Market Size is expanding rapidly, with a CAGR of 12.2% from 2023 to 2030May 5, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 [New Report forecast 2030] Current and Future TrendsMay 3, 2023 | msn.comEli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also RisesMay 3, 2023 | marketwatch.comAcute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis and Forecast to 2031May 3, 2023 | marketwatch.comCancer Drugs Market Applications and Types with Regional Analysis 2023-2031See More Headlines Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/28/2016Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ARIA CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report ARIA Stock Analysis - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) posted its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to the consensus estimate of $60.64 million. The company's revenue for the quarter was up 133.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Twitter (TWTR), Exelixis (EXEL), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals (ACHN), Array Technologies (ARRY), Alphabet (GOOG), Netflix (NFLX) and Ford Motor (F). This page (NASDAQ:ARIA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & CompanyKeep Your Eyes on This Power-Mad PoliticianAltimetry"The Biggest Drug Ever" Is ComingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
